CurrentUnitedHealthcarePolicy CS029TN.S

Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Tennessee Only)

Defines UnitedHealthcare Tennessee Medicaid/CoverKids policy on the use of ductal lavage, nipple aspirate fluid analysis, and fiberoptic ductoscopy for breast cancer screening or diagnosis; applies to Tennessee Medicaid and CoverKids providers and members.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Tennessee Only)

Policy CodePolicy CS029TN.S

Change TypeRevised (non-material)

Effective DateSep 1, 2025

Next Review DateN/A

Key ActionDo not use ductal lavage, nipple aspirate fluid cytology, or fiberoptic ductoscopy for breast cancer screening or diagnosis as they are considered unproven and not medically necessary.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

3procedures listed as unproven/not medically necessary

19499example CPT code listed

38.9%NAF inadequate sample rate

0.97NAF cytology specificity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

pooled ductoscopy sensitivity

Coverage Criteria

Unproven / Not Medically Necessary

Not medically necessary / Unproven when used for breast cancer screening, diagnosis, or as alternative tools to guide surgery.

Primary stance: Breast ductal lavage; breast ductal fluid aspiration and cytology (including nipple aspirate fluid analysis); and fiberoptic ductoscopy (with or without ductal lavage) are unproven and not medically necessary for breast cancer screening, breast cancer diagnosis, or to guide surgery due to insufficient evidence of efficacy.

Supported by evidence of low sensitivity, high rates of inadequate or inconclusive samples, limited ductal sampling, technical challenges, and lack of data showing improved detection, earlier stage at diagnosis, or reduced mortality; NCCN does not recommend ductal lavage and nipple smear cytology is not routinely recommended for nipple discharge without palpable symptom.

Use of breast ductal lavage, breast ductal fluid aspiration and cytology, and fiberoptic ductoscopy for breast cancer screening, breast cancer diagnosis, or as alternative tools to guide surgery is excluded because these interventions are considered unproven and not medically necessary due to insufficient evidence of efficacy.

The published evidence for fiberoptic ductoscopy (FDS) is limited to small, preliminary, and single-center studies focused on technical feasibility and diagnostic accuracy. FDS is technically challenging, examines only a small portion of the ductal system, and often cannot access peripheral lesions. There is no high-quality evidence that FDS improves breast cancer detection rates, leads to earlier stage at diagnosis, or reduces breast cancer mortality; larger, well-designed prospective trials are needed to establish outcome benefits.

Ductal lavage, nipple aspirate fluid (NAF) cytology, and fiberoptic ductoscopy are considered not medically necessary for breast cancer screening, diagnosis, or as alternatives to guide surgery. Studies report low sensitivity, high rates of inadequate or inconclusive samples, limited ductal sampling, and inconsistent correlation with malignancy, with no demonstrated improvement in cancer detection outcomes or mortality.

The FDA has stated that nipple aspirate tests are not substitutes for mammograms. Nipple aspirate fluid (NAF) testing alone should not replace standard mammographic screening; FDA consumer guidance emphasizes that mammography remains the established screening modality.

Coding

Applicable CPT Codes (reference)CPT

19499

Unlisted procedure, breast

Provider Actions & Billing Guidance

Prior Authorization

Prior authorization expectation

For Tennessee Medicaid/CoverKids, breast ductal lavage, breast ductal fluid aspiration and cytology, and fiberoptic ductoscopy (with or without ductal lavage) are considered unproven and not medically necessary for breast cancer screening, diagnosis, or as tools to guide surgery. Prior authorization is not expected for these services under Tennessee Medicaid/CoverKids because they are not considered medically necessary.

Breast ductal lavage
Breast ductal fluid aspiration and cytology
Fiberoptic ductoscopy, with or without ductal lavage

Documentation Required

Coding/documentation note

CPT 19499 (Unlisted procedure, breast) is listed for reference. Inclusion of this code does not guarantee coverage — submit supporting clinical documentation when billing to justify medical necessity.

CPT 19499 — Unlisted procedure, breast

Background

Cytologic examination of epithelial cells from breast ductal fluids — obtained by ductal lavage (DL), nipple aspiration/NAF, or fiberoptic ductoscopy (FDS) — has been studied as a potential early indicator of breast cancer. Evidence demonstrates important limitations: NAF cytology has poor sensitivity and a high proportion of inadequate samples, ductal lavage yields a high percentage of inconclusive results and low sensitivity, and FDS is technically challenging with restricted ductal visualization. Collectively, available studies do not show that these techniques improve detection of breast cancer, change stage at diagnosis, or affect mortality, and further longitudinal, prospective research would be required to validate clinical utility and oncologic outcomes.

Definitions

Ductal lavage — definition and brief description

DefinitionDuctal lavage (DL): invasive procedure that removes ductal fluid by inserting a microcatheter into the breast ducts via the nipple for cytologic analysis.

PurposeObtain ductal epithelial cells for cytologic examination as a potential early indicator of breast cancer.

Procedure characteristicsInvasive, performed via the nipple using a microcatheter; may be uncomfortable and technically specialized.

Nipple aspirate fluid (NAF) — definition and brief description

DefinitionNipple aspirate fluid (NAF): ductal fluid collected from the nipple either noninvasively or via fine-needle aspiration for cytologic or biomarker analysis.

Clinical use studied

Revision History

2025-09-01RevisionLatest

Updated Description of Services, Clinical Evidence, FDA, and References sections; archived prior version CS029TN.R.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Tennessee Only)

Policy CodePolicy CS029TN.S

Change TypeRevised (non-material)

Effective DateSep 1, 2025

Next Review DateN/A

Key ActionDo not use ductal lavage, nipple aspirate fluid cytology, or fiberoptic ductoscopy for breast cancer screening or diagnosis as they are considered unproven and not medically necessary.

SourceLink

On This Page

Denial Risk

Denial triggers

Use of ductal lavage, breast ductal fluid aspiration and cytology, and fiberoptic ductoscopy for breast cancer screening, diagnosis, or as surgical guidance are actions with high risk for denial when billed for coverage. Verify plan-specific rules and applicable federal, state, or contractual benefit terms before submitting claims.

Denial-risk services: ductal lavage; breast ductal fluid aspiration and cytology; fiberoptic ductoscopy

Note

Verify prior authorization

This policy is informational. Coverage determinations must reference and defer to federal, state, or contractual benefit plan terms when those terms differ from this policy. UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in administering benefits — verify prior authorization and plan rules as applicable.

Check governing benefit terms before determining coverage
UnitedHealthcare may use InterQual or other tools — verify authorization requirements

Step Therapy

Step therapy

No explicit step therapy requirements are specified in this document.

Note

Check governing benefit terms

Coverage determinations must reference federal, state, or contractual benefit requirements; in the event of conflict, those requirements govern.

Used for cytologic assessment and image analysis as a potential early indicator of breast cancer, sometimes compared or combined with ductoscopy specimens.

LimitationsStudies report low sensitivity in some cohorts and potential for false positives in patients with pathologic nipple discharge (PND).

Fiberoptic ductoscopy — definition and brief description

DefinitionFiberoptic ductoscopy (FDS): direct visualization of breast ducts using a very thin endoscope to evaluate the intraductal space.

Adjunct usesMay be performed in conjunction with aspiration cytology, biopsy, or surgical excision to evaluate abnormal nipple discharge or intraductal lesions.

Procedure limitationsTechnically challenging, potentially uncomfortable, examines only a small portion of the ductal system, and has a steep learning curve limiting widespread use.

NAF — short label entry (Nipple Aspirate Fluid)

Short labelNipple Aspirate Fluid (NAF)

ContextSpecimen type collected for cytologic and image analysis in breast cancer detection studies.

Alternate termNipple aspiration

FDS — short label entry (Fiberoptic Ductoscopy)

Short labelFDS (Fiberoptic Ductoscopy)

PurposeEndoscopic visualization of mammary ducts to identify intraductal lesions and guide management in pathologic nipple discharge (PND).

LimitationsNo high-quality evidence FDS improves cancer detection rates or mortality; further studies needed.